# EDGAR Filing Document

**Accession Number:** 0001672619
**File Stem:** 0001193125-25-140305
**Filing Date:** 2025-6
**Character Count:** 27790
**Document Hash:** 5dcf16bb5d0e89b0731158351c0a3e01
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-140305.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001193125-25-140305

**CONFORMED SUBMISSION TYPE**: S-3MEF

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**EFFECTIVENESS DATE**: 20250613

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Enliven Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001672619
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 811523849
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-3MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287994
- **FILM NUMBER:** 251044697

**BUSINESS ADDRESS:**
- **STREET 1:** 6200 LOOKOUT ROAD
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** 720-647-8519

**MAIL ADDRESS:**
- **STREET 1:** 6200 LOOKOUT ROAD
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** IMARA Inc.
- **DATE OF NAME CHANGE:** 20160419

**As filed with the Securities and Exchange Commission on June 13, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-3**

**REGISTRATION STATEMENT** 

***Under***

***The Securities Act of 1933***

## Enliven Therapeutics, Inc.
**(Exact name of Registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **81-1523849** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification Number)** |

---

**6200 Lookout Road** 

**Boulder, CO 80301** 

**(720) 647-8519**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Samuel Kintz** 

**President and Chief Executive Officer** 

**Enliven Therapeutics, Inc.** 

**6200 Lookout Road** 

**Boulder, CO 80301** 

**(720) 647-8519**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***Copies to:***

**Tony Jeffries, Esq.** 

**Jennifer Knapp, Esq.** 

**Wilson Sonsini Goodrich & Rosati** 

**Professional Corporation** 

**1881 9th Street, Suite 110** 

**Boulder, CO 80302** 

**(303) 256-5900**

**Approximate date of commencement of proposed sale to the public**: From time to time after the effective date of the registration statement.

If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File no. 333-272909)

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☒ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

**This Registration Statement shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act.** 

------

**EXPLANATORY NOTE AND INCORPORATION BY REFERENCE** 

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the registrant is filing this Registration Statement on Form S-3 to register the offer and sale of an additional $40,000,000, or the equivalent thereof, of its (a) shares of the Company's common stock, $0.001 par value per share (the "Common Stock"); (b) shares of the Company's preferred stock, $0.001 par value per share (the "Preferred Stock"); (c) the Company's debt securities (the "Debt Securities"); (d) depositary shares of the Company representing a fractional interest in a share of Preferred Stock (the "Depositary Shares"); (e) warrants to purchase Common Stock, Preferred Stock, Debt Securities or Depositary Shares (the "Warrants"); (f) subscription rights to purchase Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants or units consisting of some or all of these securities (the "Subscription Rights"); (g) purchase contracts of the Company with respect to the securities of the Company (the "Purchase Contracts"); and (h) units consisting of two or more securities described above in any combination (the "Units") (the Common Stock, the Preferred Stock, the Debt Securities, the Depositary Shares, the Warrants, the Subscription Rights, the Purchase Contracts and the Units are collectively referred to herein as the "Securities"). This Registration Statement relates to the registrant's Registration Statement on [<u>Form S-3</u>](http://www.sec.gov/Archives/edgar/data/1710072/000110465922041797/tm2210736d1_s3.htm) (File No. 333-272909) (the "Prior Registration Statement"), initially filed on June 23, 2023 and declared effective by the Securities and Exchange Commission on July 3, 2023. The required opinion and consents are filed herewith. The additional amount of Securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

ii

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| **Exhibit<br>Number** | **Exhibit Description** |
| 5.1 | [Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation](d15556dex51.htm) |
| 23.1 | [Consent of Independent Registered Public Accounting Firm](d15556dex231.htm) |
| 23.2 | [Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (included in Exhibit 5.1)](d15556dex51.htm) |
| 107.1 | [Filing Fee Table](d15556dexfilingfees.htm) |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on June 13, 2025.

---

| | |
|:---|:---|
| **ENLIVEN THERAPEUTICS, INC.** | **ENLIVEN THERAPEUTICS, INC.** |
| By: | /s/ Samuel Kintz |
|  | Samuel Kintz |
|  | President and Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated:

------

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Samuel Kintz<br> Samuel Kintz | President, Chief Executive Officer and Director (Principal Executive Officer) | June 13, 2025 |
| /s/ Benjamin Hohl<br> Benjamin Hohl | Chief Financial Officer<br> (Principal Financial and Accounting Officer) | June 13, 2025 |
| \*<br> Richard Heyman, Ph.D. | Chairman of the Board of Directors and Director | June 13, 2025 |
| \*<br> Rahul Ballal, Ph.D. | Director | June 13, 2025 |
| \*<br> Jacob Bauer | Director | June 13, 2025 |
| \*<br> Mika Derynck, M.D. | Director | June 13, 2025 |
| \*<br> Rishi Gupta, J.D. | Director | June 13, 2025 |
| \*<br> Lori Kunkel, M.D. | Director | June 13, 2025 |
| \*<br> Andrew Phillips, Ph.D. | Director | June 13, 2025 |

---

---

| | |
|:---|:---|
| \*By: | /s/ Samuel Kintz |
|  | Samuel Kintz |
|  | President and Chief Executive Officer<br> Attorney-in-Fact |

---

## Exhibit 5.1

**Exhibit 5.1** 

---

| | |
|:---|:---|
| ![LOGO](g15556g0612215853952.jpg) | Wilson Sonsini Goodrich & Rosati<br> Professional Corporation<br>1155 Canyon Blvd., Suite 400<br> Boulder, CO 80302-5148<br>o: 303.256.5900<br> f: 866.974.7329 |

---

June 13, 2025

Enliven Therapeutics, Inc.

6200 Lookout Road

Boulder, Colorado 80301

**Re: <u>Registration Statement on Form S-3</u>**

Ladies and Gentlemen:

This opinion is furnished to you in connection with the Registration Statement on Form S-3 (the "***Registration Statement***"), filed by Enliven Therapeutics, Inc. (the "***Company***") with the U.S. Securities and Exchange Commission (the "***Commission***") pursuant to Rule 462(b) of the Securities Act of 1933, as amended (the "***Securities Act***"), in connection with the registration under the Securities Act of additional (a) shares of the Company's common stock, $0.001 par value per share (the "***Common Stock***"); (b) shares of the Company's preferred stock, $0.001 par value per share (the "***Preferred Stock***"); (c) the Company's debt securities (the "***Debt Securities***"); (d) depositary shares of the Company representing a fractional interest in a share of Preferred Stock (the "***Depositary Shares***"); (e) warrants to purchase Common Stock, Preferred Stock, Debt Securities or Depositary Shares (the "***Warrants***"); (f) subscription rights to purchase Common Stock, Preferred Stock, Debt Securities, Depositary Shares, Warrants or units consisting of some or all of these securities (the "***Subscription Rights***"); (g) purchase contracts of the Company with respect to the securities of the Company (the "***Purchase Contracts***"); and (h) units consisting of two or more securities described above in any combination (the "***Units***") (the Common Stock, the Preferred Stock, the Debt Securities, the Depositary Shares, the Warrants, the Subscription Rights, the Purchase Contracts and the Units are collectively referred to herein as the "***Securities***"), with an aggregate offering price of $40,000,000.00. The Registration Statement incorporates by reference the Registration Statement on Form S-3 (Registration No. 333-272909) (the "***Prior Registration Statement***"), which was declared effective on July 3, 2023, including the prospectus which forms part of the Registration Statement (the "***Prospectus***") and the supplements to the prospectus referred to therein (each a "***Prospectus Supplement***").

The Securities are to be sold from time to time as set forth in the Registration Statement, the Prospectus contained therein and the Prospectus Supplements. The Debt Securities are to be issued pursuant to a debt securities indenture (the "***Indenture***"), a form of which has been filed as an exhibit to the Prior Registration Statement and is to be entered into between the Company and a trustee to be named in a Prospectus Supplement to the Registration Statement (the "***Trustee***"). The Securities are to be sold pursuant to a purchase, underwriting or similar agreement in substantially the form to be filed under a Current Report on Form 8-K. The Debt Securities are to be issued in the form set forth in the Indenture. The Indenture may be supplemented in connection with the issuance of each such series of Debt Securities, by a supplemental indenture or other appropriate action of the Company creating such series of Debt Securities.

AUSTIN BOSTON BOULDER BRUSSELS HONG KONG LONDON LOS ANGELES NEW YORK PALO ALTO

SALT LAKE CITY SAN DIEGO SAN FRANCISCO SEATTLE SHANGHAI WASHINGTON, DC WILMINGTON, DE

------

Enliven Therapeutics, Inc.

June 13, 2025

We have examined instruments, documents, certificates and records that we have deemed relevant and necessary for the basis of our opinions hereinafter expressed. In such examination, we have assumed: (a) the authenticity of original documents and the genuineness of all signatures; (b) the conformity to the originals of all documents submitted to us as copies; (c) the truth, accuracy and completeness of the information, representations and warranties contained in the instruments, documents, certificates and records we have reviewed; (d) that the Registration Statement, and any amendments thereto (including post-effective amendments), will have become effective under the Act; (e) that a Prospectus Supplement will have been filed with the Commission describing the Securities offered thereby; (f) that the Securities will be issued and sold in compliance with applicable U.S. federal and state securities laws and in the manner stated in the Registration Statement and the applicable Prospectus Supplement; (g) that a definitive purchase, underwriting or similar agreement with respect to any Securities offered will have been duly authorized and validly executed and delivered by the Company and the other parties thereto; (h) that any Securities issuable upon conversion, exchange, redemption or exercise of any Securities being offered will be duly authorized, created and, if appropriate, reserved for issuance upon such conversion, exchange, redemption or exercise; (i) with respect to shares of Common Stock or Preferred Stock, that there will be sufficient shares of Common Stock or Preferred Stock authorized under the Company's organizational documents that are not otherwise reserved for issuance; and (j) the legal capacity of all natural persons. As to any facts material to the opinions expressed herein that were not independently established or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company. The term "Board" means the Board of Directors of the Company or a duly constituted and acting committee thereof.

Based on such examination, we are of the opinion that:

1. With respect to the shares of Common Stock, when: (a) the Board has taken all necessary corporate action
to approve the issuance and the terms of the offering of the shares of Common Stock and related matters; and (b) the shares of Common Stock have been duly delivered either (i) in accordance with the applicable definitive purchase,
underwriting or similar agreement approved by the Board, or upon the exercise of Warrants to purchase Common Stock, upon payment of the consideration therefor (not less than the par value of the Common Stock) provided for therein or (ii) upon
conversion or exercise of any other Security, in accordance with the terms of such Security or the instrument governing such Security providing for such conversion or exercise as approved by the Board, for the consideration approved by the Board,
then the shares of Common Stock will be validly issued, fully paid and nonassessable.

2. With respect to any particular series of shares of Preferred Stock, when: (a) the Board has taken all
necessary corporate action to approve the issuance and terms of the shares of Preferred Stock, the terms of the offering thereof, and related matters, including the adoption of a certificate of designation (a "  ***Certificate*** ")
relating to such Preferred Stock conforming to the General Corporation Law of the State of Delaware (the "  ***DGCL***") and the filing of the Certificate with the Secretary of State of the State of Delaware; and (b) the shares
of Preferred Stock have been duly delivered either (i) in accordance with the applicable definitive purchase, underwriting or similar agreement approved by the Board, or upon the exercise of Warrants to purchase Preferred Stock, upon payment of
the consideration therefor (not less than the par value of the Preferred Stock) provided for therein or (ii) upon conversion or exercise of any other Security, in accordance with the terms of such Security or the instrument governing such
Security providing for such conversion or exercise as approved by the Board, for the consideration approved by the Board, then the shares of Preferred Stock will be validly issued, fully paid and nonassessable.

3. With respect to Debt Securities to be issued under the Indenture, when: (a) the Trustee is qualified to
act as Trustee under the Indenture and the Company has filed a Form T-1 for the Trustee with the Commission; (b) the Trustee has duly executed and delivered the Indenture; (c) the Indenture has
been duly authorized and validly executed and delivered by the Company to the Trustee; (d) the Indenture has been duly qualified under the Trust Indenture Act of 1939, as amended; (e) the Board has taken all necessary corporate action
to approve the issuance and terms of such Debt Securities, the terms of the offering thereof and related matters; and (f) such Debt Securities have been duly executed, authenticated, issued and delivered in accordance with the provisions of the
Indenture and the applicable definitive purchase, underwriting or similar agreement approved by the Board, or upon the exercise of Warrants to purchase Debt Securities, upon payment of the consideration therefor provided for therein, such Debt
Securities will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, and entitled to the benefits of the Indenture.

------

Enliven Therapeutics, Inc.

June 13, 2025

4. With respect to Depositary Shares, when: (a) the Board has taken all necessary corporate action to approve
the issuance and terms of the Depositary Shares, the terms of the offering thereof, and related matters, including the adoption of a Certificate relating to the Preferred Stock underlying such Depositary Shares and the filing of the Certificate with
the Secretary of State of the State of Delaware; (b) the Deposit Agreement (the "Deposit Agreement") or agreements relating to the Depositary Shares and the related Depositary Receipts (the "Depositary Receipts") have been
duly authorized and validly executed and delivered by the Company and the depositary appointed by the Company; (c) the shares of Preferred Stock underlying such Depositary Shares have been deposited with a bank or trust company (which meets the
requirements for the depositary set forth in the Registration Statement) under the applicable Deposit Agreement; and (d) the Depositary Receipts representing the Depositary Shares have been duly executed, countersigned, registered and delivered
in accordance with the appropriate Deposit Agreement and the applicable definitive purchase, underwriting or similar agreement approved by the Board upon payment of the consideration therefor provided for therein, the Depositary Shares will be
validly issued, fully paid and nonassessable.

5. With respect to the Warrants, when: (a) the Board has taken all necessary corporate action to approve the
issuance and terms of the Warrants and related matters; and (b) the Warrants have been duly executed and delivered against payment therefor, pursuant to the applicable definitive purchase, underwriting, warrant or similar agreement, as
applicable, duly authorized, executed and delivered by the Company and a warrant agent and the certificates for the Warrants have been duly executed and delivered by the Company and such warrant agent, then the Warrants will constitute valid and
binding obligations of the Company, enforceable against the Company in accordance with their terms.

6. With respect to the Subscription Rights, when: (a) the Board has taken all necessary corporate action to
authorize the issuance and terms of the Subscription Rights, the terms of the offering thereof, and related matters and (b) the rights agreement under which the Subscription Rights are to be issued has been duly authorized and validly executed
and delivered by the Company, and upon payment of the consideration for the Subscription Rights provided for in such rights agreement, if any, then the Subscription Rights will be valid and binding obligations of the Company, enforceable against the
Company in accordance with their terms.

7. With respect to the Purchase Contracts, when: (a) the Board has taken all necessary corporate action to
approve the issuance and terms of the Purchase Contracts and related matters and (b) the agreement under which the Purchase Contracts are to be issued has been duly authorized and validly executed and delivered by the Company, then the Purchase
Contracts will be valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

8. With respect to the Units, when: (a) the Board has taken all necessary corporate action to approve the
issuance and terms of the Units (including any Securities underlying the Units) and related matters; and (b) the Units (including any Securities underlying the Units) have been duly executed and delivered against payment therefor, pursuant to
the applicable definitive purchase, underwriting, or similar agreement duly authorized, executed and delivered by the Company and any applicable unit or other agents, and the certificates for the Units (including any Securities underlying the Units)
have been duly executed and delivered by the Company and any applicable unit or other agents, then the Units will constitute valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.

Our opinion that any document is legal, valid and binding is qualified as to:

a) limitations imposed by bankruptcy, insolvency, reorganization, arrangement, fraudulent transfer, moratorium or
other similar laws relating to or affecting the rights of creditors generally;

b) rights to indemnification and contribution, which may be limited by applicable law or equitable principles; and

c) the effect of general principles of equity, including without limitation concepts of materiality,
reasonableness, good faith and fair dealing, and the possible unavailability of specific performance or injunctive relief, whether considered in a proceeding in equity or at law.

------

Enliven Therapeutics, Inc.

June 13, 2025

We express no opinion herein as to the laws of any state or jurisdiction other than the DGCL, the federal laws of the United States of America and the laws of the State of New York as to the enforceability of the Debt Securities.

We consent to the use of this opinion as an exhibit to the Registration Statement, and we consent to the reference of our name wherever it appears in the Registration Statement, Prior Registration Statement, Prospectus, any Prospectus Supplement, and in any amendment or supplement thereto. In giving this consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Wilson Sonsini Goodrich & Rosati, P.C. |
| WILSON SONSINI GOODRICH & ROSATI |
| Professional Corporation |

---

## Exhibit 23.1

**Exhibit 23.1** 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM** 

We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 13, 2025, relating to the financial statements of Enliven Therapeutics, Inc. appearing in the Registration Statement No. 333-272909 on Form S-3 of Enliven Therapeutics, Inc.

---

| |
|:---|
|  /s/ Deloitte & Touche, LLP |
|  San Francisco, California |
|  June 13, 2025 |

---

## Ex-Filing

**Exhibit 107.1** 

Calculation of Filing Fee Tables

**FORM S-3** 

(Form Type)

**ENLIVEN THERAPEUTICS, INC.** 

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | Security<br> Type | Security<br> Class<br> Title | Fee<br> Calculation<br> Rule | Maximum<br> Aggregate<br> Offering<br> Price | Fee<br> Rate | Amount of<br> Registration<br> Fee |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Equity | Common Stock, par<br> value $0.001 per<br> share | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Equity | Preferred Stock, par<br> value $0.001 per<br> share | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Debt | Debt Securities | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Equity | Depositary Shares | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Other | Warrants | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Other | Subscription Rights | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Other | Purchase Contracts | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Other | Units | 457(o)<sup>(1)</sup> | <sup>(1)</sup> |  |  |
| &nbsp;&nbsp;&nbsp;Fees to Be Paid | Unallocated<br> (Universal<br> Shelf) | Unallocated<br> (Universal Shelf) | 457(o)<sup>(1)</sup> | $40000000 <sup>(1)</sup> | $0.0001531 | $6124 |
|  | Total Offering Amounts | Total Offering Amounts | Total Offering Amounts | $40000000 <sup>(1)</sup> | $0.0001531 | $6124 |
|  | Total Fees Previously Paid | Total Fees Previously Paid | Total Fees Previously Paid | $0 |  |  |
|  | Total Fee Offsets | Total Fee Offsets | Total Fee Offsets |  |  |  |
|  | Net Fee Due | Net Fee Due | Net Fee Due |  |  | $6124 |

---

(1) The registrant previously registered the offer and sale of certain securities having a proposed maximum aggregate
offering price of $400,000,000 pursuant to a Registration Statement on Form S-3 (File No. 333-272909) (the "Prior Registration Statement"), which was initially filed on June 23, 2023 and
declared effective by the Securities and Exchange Commission on July 3, 2023. As of the date hereof, a balance of $200,000,000.00 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the
Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the registrant is hereby registering the offer and sale of an additional $40,000,000.00 of its Securities. The additional amount
of Securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement.